Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium

• Published in: Blood advances Vol. 5; no. 20; pp. 4278 - 4284
• Main Authors: DeFilipp, Zachariah, Alousi, Amin M., Pidala, Joseph A., Carpenter, Paul A., Onstad, Lynn E., Arai, Sally, Arora, Mukta, Cutler, Corey S., Flowers, Mary E.D., Kitko, Carrie L., Chen, George L., Lee, Stephanie J., Hamilton, Betty K.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.10.2021; American Society of Hematology
• Subjects: Graft vs Host Disease - diagnosis; Graft vs Host Disease - etiology; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Neoplasm Recurrence, Local; Prospective Studies; Transplantation; Transplantation Conditioning
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2021004941

Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. To better understand patients at highest risk for nonrelapse mortality (NRM), we analyzed patient-, transplant-, and cGVHD-related variables, risk factors, and causes of nonrelapse deaths in an updated cohort of 937 patients enrolled on 2 prospective, longitudinal observational studies through the Chronic GVHD Consortium. The median follow-up of survivors was 4 years (range, 0.1 months to 12.5 years). Relapse accounted for 25% of the 333 deaths. The cumulative incidence of NRM was 22% at 5 years, and it increased over time at a projected 40% (95% confidence interval, 30%-50%) at 12 years. Centers reported that cGVHD (37.8%) was the most common cause of NRM and was associated with organ failure, infection, or additional causes not otherwise specified. The next most frequent causes without mention of cGVHD were infection (17%) and respiratory failure (10%). In multivariable analysis, an increased risk for NRM was significantly associated with the use of reduced intensity conditioning, higher total bilirubin, National Institutes of Health (NIH) skin score of 2 to 3, NIH lung score of 1 to 3, worse modified Human Activity Profile adjusted activity score, and decreased distance on walk test. To summarize, cGVHD NRM does not plateau but increases over time and is most commonly attributed to GVHD or infection, presumably associated with immunocompromised status. Severe skin and lung cGVHD remain challenging manifestations associated with increased NRM, for which novel therapeutic options that do not predispose patients to infections are needed. •NRM increases without apparent plateau in patients with cGVHD.•The most common reported causes of death were cGVHD and infection. [Display omitted]